Fulgent Genetics Current Valuation vs. EBITDA
| FLGT Stock | USD 19.58 0.66 3.26% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.44 | 0.3612 |
|
|
For Fulgent Genetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Fulgent Genetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Fulgent Genetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Fulgent Genetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Fulgent Genetics over time as well as its relative position and ranking within its peers.
Fulgent |
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulgent Genetics. If investors know Fulgent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulgent Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share (5.52) | Revenue Per Share 9.255 | Quarterly Revenue Growth (0.15) | Return On Assets (0.04) |
The market value of Fulgent Genetics is measured differently than its book value, which is the value of Fulgent that is recorded on the company's balance sheet. Investors also form their own opinion of Fulgent Genetics' value that differs from its market value or its book value, called intrinsic value, which is Fulgent Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulgent Genetics' market value can be influenced by many factors that don't directly affect Fulgent Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulgent Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulgent Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulgent Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fulgent Genetics EBITDA vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Fulgent Genetics's current stock value. Our valuation model uses many indicators to compare Fulgent Genetics value to that of its competitors to determine the firm's financial worth. Fulgent Genetics is rated # 3 in current valuation category among its peers. It also is rated # 3 in ebitda category among its peers . At this time, Fulgent Genetics' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Fulgent Genetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fulgent Current Valuation vs. Competition
Fulgent Genetics is rated # 3 in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 12.35 Billion. Fulgent Genetics holds roughly 394.87 Million in current valuation claiming about 3% of equities under Health Care industry.
Fulgent EBITDA vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Fulgent Genetics |
| = | 394.87 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Fulgent Genetics |
| = | (46.55 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Fulgent EBITDA Comparison
Fulgent Genetics is currently under evaluation in ebitda category among its peers.
Fulgent Genetics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Fulgent Genetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Fulgent Genetics will eventually generate negative long term returns. The profitability progress is the general direction of Fulgent Genetics' change in net profit over the period of time. It can combine multiple indicators of Fulgent Genetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.2 M | 1.3 M | |
| Operating Income | -72.7 M | -69.1 M | |
| Net Loss | -65 M | -61.7 M | |
| Income Before Tax | -174.1 M | -165.4 M | |
| Total Other Income Expense Net | -101.4 M | -96.3 M | |
| Net Income Applicable To Common Shares | 164.9 M | 101.5 M | |
| Net Loss | -167.8 M | -159.4 M | |
| Income Tax Expense | 1.2 M | 1.1 M | |
| Interest Income | 18.6 M | 19.5 M | |
| Net Interest Income | 18.6 M | 19.5 M | |
| Non Operating Income Net Other | 5.8 M | 6.1 M | |
| Change To Netincome | 86.8 M | 91.1 M | |
| Net Loss | (5.63) | (5.35) | |
| Income Quality | (0.16) | (0.17) | |
| Net Income Per E B T | 0.96 | 1.45 |
Fulgent Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Fulgent Genetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Fulgent Genetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Fulgent Genetics' important profitability drivers and their relationship over time.
Use Fulgent Genetics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fulgent Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fulgent Genetics will appreciate offsetting losses from the drop in the long position's value.Fulgent Genetics Pair Trading
Fulgent Genetics Pair Trading Analysis
The ability to find closely correlated positions to Fulgent Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fulgent Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fulgent Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fulgent Genetics to buy it.
The correlation of Fulgent Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fulgent Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fulgent Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fulgent Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Fulgent Genetics position
In addition to having Fulgent Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Penny Thematic Idea Now
Penny
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.